Connect with us

Biotech

GenesisCare Invests Five Million in Technology at its Castilla-La Mancha Centers

GenesisCare has more than 350 oncology centers around the world. The works have meant a great qualitative leap forward, equipping the Alcázar de San Juan center with innovative technology such as a state-of-the-art Elekta Versa HD linear accelerator that allows techniques such as stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (Sbrt), as well as volumetric modulated radiotherapy (Vmat).

Published

on

GenesisCare renews the technology park at its centers in Castilla-La Mancha. The radiation oncology provider reinforces its commitment to Castilla-La Mancha with an investment of nearly $5.5 million (€5 million) in the last year in the region. The technological renovation includes the centers in Alcázar de San Juan, Talavera de la Reina and Guadalajara.

The company has earmarked $2.75 million (€2.5 million) for technological improvements and renovation work at its radiotherapy oncology center in Alcázar de San Juan, which treats more than 400 patients a year.

The renovation began in 2021, with the aim of offering the latest treatments, as well as modern and comfortable facilities for cancer patients in the region of Alcázar de San Juan, and the nearby municipalities of Ciudad Real, Cuenca, and Toledo, such as Tomelloso or Manzanares. The center is scheduled to open its doors in mid-April. Members of the global executive committee will visit the facilities shortly and will participate in the official opening ceremony in early May.

Read more about the latest investments in technology that the company GenesisCare has made and find the most important business headlines in the world with our companion app Born2Invest.

GenesisCare has more than 350 oncology centers around the world

The works have meant a great qualitative leap forward, equipping the Alcázar de San Juan center with innovative technology such as a state-of-the-art Elekta Versa HD linear accelerator that allows techniques such as stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (Sbrt), as well as volumetric modulated radiotherapy (Vmat).

This technology allows high treatment doses, up to three times higher than conventional doses. In this way, hypofractionated treatments can be offered, which means a smaller number of sessions, according to medical prescription. The company has also equipped the center with a new General Electric Discovery RT computed tomography (CT) system to enable 4D treatment planning.

SEE ALSO  Your 2020 guide on how to get the most out of video marketing

Brendan Capell, CEO of GenesisCare, explained that “we continue with our center renovation strategy to offer our patients the latest technology, the best professionals for personalized treatment, as well as an excellent experience during their visit to the center.”

In addition, as part of the renovation of the Castilla-La Mancha region, a new General Electric Discovery RT planning CT was installed last year at the Guadalajara center and the company is, in turn, renovating the Talavera de la Reina center, which will be completed by the end of this year.

The company has more than 350 oncology centers around the world: more than 300 in the United States, more than thirty in Australia, and more than ten in the United Kingdom, in addition to more than fifteen in Spain. On a global scale, the company has more than 5,000 doctors and treats more than 450,000 patients a year.

__

(Featured image by Bokskapet via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Olivia McCall is passionate about education, women and children’s rights, and the environment. A long-time investor, she covers news about the latest stocks (lately marijuana and tech), IPOs and indices, and is always on the lookout for socially responsible startups. She also writes about the food sector, and has a keen interest on cryptocurrencies.

Continue Reading